ABSTRACT
It has been realized among the scientific community in the past several years that a successful high throughput screening program depends upon the size and diversity of the compound collection and the number of screening assays. The utilization of automated high throughput assays has created a demand for small organic molecules. The demand exceeds the output generated by traditional synthesis methods employed by many medicinal chemists. To meet the demand, various techniques are being developed to generate large numbers of small organic molecules via automation of organic synthesis. Both solution phase and solid phase strategies are employed for lead discovery and optimization in many therapeutic areas (1).
